Genetic Factors Linked to Melanoma Response to T-VEC Treatment
Author Information
Author(s): Sierra-Davidson Kailan MD, DPHIL, Dedeilia Aikaterini MD, Lawless Aleigha RN, Sharova Tanya MD, Kaufman Howard L. MD, Boland Genevieve M. MD, PHD, Cohen Sonia MD, PHD
Primary Institution: Massachusetts General Hospital, Harvard Medical School
Hypothesis
Are there tumor-intrinsic genetic factors associated with tumor control in melanoma patients treated with T-VEC?
Conclusion
TERT promotor mutations may drive clinical response in melanoma patients treated with T-VEC.
Supporting Evidence
- 30% of patients had a complete response to T-VEC treatment.
- Stage III disease was significantly associated with clinical response.
- Absence of visceral or CNS metastases was linked to better outcomes.
Takeaway
This study looked at melanoma patients treated with a special virus to see if certain genetic changes in their tumors helped them respond better to the treatment.
Methodology
A retrospective analysis of melanoma patients treated with T-VEC, collecting demographic, clinical, and genomic data.
Potential Biases
Referral bias and potential underpowering to detect additional prognostic markers.
Limitations
The study is limited to a single institution and may have biases based on referral patterns.
Participant Demographics
{"male":37,"female":32,"median_age":78,"age_distribution":{"under_60":6,"60_to_80":34,"over_80":29}}
Statistical Information
P-Value
p=0.043
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website